Roles and mechanisms of circular RNA in respiratory system cancers

Nan Yang, Meng-Wen Jiao, Yuewen Zhang, Shaokang Mo, Ling Wang, Jianqing LiangFrontiers in Oncology 2024 · DOI

TL;DR

This review synthesizes the rapidly evolving landscape of circular RNAs (circRNAs) in respiratory cancers, highlighting how these stable, covalently closed RNA loops have transitioned from being dismissed as "splicing noise" to being recognized as pivotal regulators of tumor progression. By acting as microRNA sponges, protein scaffolds, and even templates for translation, circRNAs offer a new frontier for highly specific biomarkers and therapeutic targets in non-small cell lung cancer (NSCLC), nasopharyngeal carcinoma (NPC), and laryngeal squamous cell carcinoma (LSCC).

What Problem Does This Paper Address?

Respiratory system cancers remain a leading cause of global mortality due to late-stage diagnosis and the development of drug resistance. While linear messenger RNAs (mRNAs) and long non-coding RNAs (lncRNAs) have been extensively studied, the role of circular RNAs—which lack the traditional 5’ cap and 3’ poly(A) tail—was largely ignored until the advent of high-throughput sequencing.

The authors address the need for a comprehensive framework that connects the unique biogenesis of circRNAs (how they are formed through "back-splicing") to their specific pathological roles in respiratory oncology. The goal is to move beyond cataloging these molecules and toward understanding the mechanical "how" behind their influence on cell proliferation, metastasis, and metabolism.

Methods

As a review article, this paper does not introduce a new experimental protocol or algorithm. Instead, it systematically aggregates and analyzes data from over 130 primary research studies. The authors categorize the literature based on:

  • Biogenesis Mechanisms: Detailing four pathways of circularization: lariat-driven, direct reverse splicing (intron pairing), RNA-binding protein (RBP)-mediated, and tricRNA biogenesis.
  • Functional Modalities: Analyzing how circRNAs function as "sponges" for miRNAs (the ceRNA hypothesis), decoys for RBPs, transcriptional regulators, or translation templates for novel peptides.
  • Disease Specificity: Mapping these functions across the three major respiratory cancers (NSCLC, NPC, and LSCC).

Datasets

The paper references several foundational datasets and bioinformatics resources used by the primary researchers it cites, including:

  • GEO (Gene Expression Omnibus): Specifically dataset GSE101684 for identifying circRNA signatures in NSCLC.
  • Transcriptome Sequencing Data: References to early landmark studies (e.g., Salzman et al., 2012) that used high-throughput sequencing of human bone marrow and various cancer cell lines to prove the ubiquity of circRNAs.

Key Insights and Ideas

  • Structural Stability as a Feature: Because circRNAs are covalently closed loops, they are resistant to Exonuclease R (RNase R), which typically degrades linear RNA. This makes them significantly more stable in the cytoplasm and blood, positioning them as superior candidates for liquid biopsy biomarkers compared to linear RNAs.
  • The ceRNA "Sponge" Effect: The most common mechanism identified is the "competing endogenous RNA" (ceRNA) model. For example, in NSCLC, circTP63 binds to miR-873-3p, preventing it from suppressing the oncogene FOXM1, thereby driving the cell cycle forward.
  • Metabolic Reprogramming: circRNAs are shown to be key players in the "Warburg Effect." In LSCC, circMYOF promotes glycolysis (glucose consumption and lactate production) via the miR-145-5p/OTX1 axis, fueling rapid tumor growth.
  • Drug Resistance Scaffolding: In NPC, circ-0067717 acts as a physical scaffold that brings together the E3 ligase TRIM41 and the tumor suppressor p53, leading to the degradation of p53 and subsequent resistance to paclitaxel.

Key Results

The review highlights several high-impact quantitative findings from the cited literature:

  • NSCLC: Knocking down circERBB2IP was shown to significantly inhibit tumor growth in vivo by modulating the miR-5195-3p/PSAT1 axis.
  • NPC: The circCAMSAP1/SERPINH1/c-Myc positive feedback loop was identified as a major driver of proliferation; c-Myc stimulates the transcription of the very genes that form the circular RNA, creating a self-sustaining oncogenic cycle.
  • LSCC: circ-CCND1 was found to physically bind to the HuR protein, increasing the stability of CCND1 mRNA and directly contributing to the high proliferation rates seen in laryngeal tumors.

Limitations and Future Work

The authors acknowledge several hurdles before circRNAs can reach the clinic:

  • Early Stage Research: Much of the current functional understanding is based on in vitro cell lines or mouse models; large-scale human clinical validation is still lacking.
  • Low Abundance: Despite their stability, many circRNAs are expressed at much lower levels than their linear counterparts, making detection and therapeutic targeting technically challenging.
  • Validation Gaps: There is a pressing need for more "omics" research to validate the interactions between circRNAs and other molecules (proteins, DNA, and other RNAs) in a high-throughput, systemic manner.
  • Delivery Systems: Developing safe and effective methods to deliver circRNA-based therapeutics (or siRNA to knock them down) remains a significant bioengineering challenge.

Summary updated

Abstract

Circular RNAs (circRNAs) constitute a class of endogenous non-coding RNAs (ncRNAs) that lack a 5'-ended cap and 3'-ended poly (A) tail and form a closed ring structure with covalent bonds. Due to its special structure, circRNA is resistant to Exonuclease R (RNaseR), making its distribution in the cytoplasm quite rich. Advanced high-throughput sequencing and bioinformatics methods have revealed that circRNA is highly conserved, stable, and disease- and tissue-specific. Furthermore, increasing research has confirmed that circRNA, as a driver or suppressor, regulates cancer onset and progression by modulating a series of pathophysiological mechanisms. As a result, circRNA has emerged as a clinical biomarker and therapeutic intervention target. This article reviews the biological functions and regulatory mechanisms of circRNA in the context of respiratory cancer onset and progression.
BibTeX
@inproceedings{yang2024roles,
  author = {Nan Yang and Meng-Wen Jiao and Yuewen Zhang and Shaokang Mo and Ling Wang and Jianqing Liang},
  title = {{Roles and mechanisms of circular RNA in respiratory system cancers}},
  booktitle = {Frontiers in Oncology},
  year = {2024},
  doi = {10.3389/fonc.2024.1430051},
}
Figure